Lindbrook Capital’s Keros Therapeutics KROS Stock Holding History

Lindbrook Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.68K	Buy	165 +76	+85%	+$882	﹤0.01%	2332
2024 Q4	$1.41K	Sell	89 -24	-21%	-$1.25K	﹤0.01%	2402
2024 Q3	$6.56K	Buy	113 +24	+27%	+$1.19K	﹤0.01%	1891
2024 Q2	$4.07K	Hold	89	–	–	﹤0.01%	2096
2024 Q1	$5.89K	Hold	89	–	–	﹤0.01%	1829
2023 Q4	$3.54K	Buy	89 +70	+368%	+$2.19K	﹤0.01%	2059
2023 Q3	$606	Buy	+19	New	+$709	﹤0.01%	2499
2023 Q1	–	Sell	-38	Closed	-$1.82K	–	2851
2022 Q4	$1.82K	Buy	38 +21	+124%	+$981	﹤0.01%	2270
2022 Q3	$1K	Buy	17 +9	+113%	+$312	﹤0.01%	2379
2022 Q2	$0	Sell	8 -9	-53%	-$395	﹤0.01%	2628
2022 Q1	$1K	Buy	+17	New	+$873	﹤0.01%	2273

Other funds holding KROS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lindbrook Capital's KROS Position: Q1 2025 in Review

Lindbrook Capital increased its Keros Therapeutics (KROS) stake by 85% in Q1 2025, buying an estimated $882 and bringing the position to 165 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

Lindbrook Capital first reported a position in KROS in Q1 2022 and has held it in 11 quarters since. The position peaked at $6.56K in Q3 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

Lindbrook Capital held 165 shares of Keros Therapeutics worth $1.68K as of Q1 2025.
Lindbrook Capital bought 76 Keros Therapeutics shares in Q1 2025, an estimated $882.
Keros Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2332 holding.
Lindbrook Capital first reported a position in Keros Therapeutics in Q1 2022 and has held it in 11 quarters since.
Lindbrook Capital's Keros Therapeutics position peaked at $6.56K in Q3 2024.
156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.